Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 19 |
| List of Tables | 17 | 3 |
| List of Figures | 20 | 1 |
| Introduction | 21 | 1 |
| Global Markets Direct Report Coverage | 21 | 1 |
| Schizophrenia Overview | 22 | 1 |
| Therapeutics Development | 23 | 2 |
| Pipeline Products for Schizophrenia Overview | 23 | 1 |
| Pipeline Products for Schizophrenia Comparative Analysis | 24 | 1 |
| Schizophrenia Therapeutics under Development by Companies | 25 | 5 |
| Schizophrenia Therapeutics under Investigation by Universities/Institutes | 30 | 1 |
| Schizophrenia Pipeline Products Glance | 31 | 4 |
| Late Stage Products | 31 | 1 |
| Clinical Stage Products | 32 | 1 |
| Early Stage Products | 33 | 1 |
| Unknown Stage Products | 34 | 1 |
| Schizophrenia Products under Development by Companies | 35 | 8 |
| Schizophrenia Products under Investigation by Universities/Institutes | 43 | 1 |
| Schizophrenia Companies Involved in Therapeutics Development | 44 | 73 |
| Adamed Sp. z o.o. | 44 | 1 |
| Aequus Pharmaceuticals Inc. | 45 | 1 |
| Aestus Therapeutics, Inc. | 46 | 1 |
| AgeneBio Inc. | 47 | 1 |
| Alkermes Plc | 48 | 1 |
| Angita B.V. | 49 | 1 |
| Astellas Pharma Inc. | 50 | 1 |
| Athersys, Inc. | 51 | 1 |
| Avanir Pharmaceuticals, Inc. | 52 | 1 |
| Avineuro Pharmaceuticals, Inc. | 53 | 1 |
| BCWorld Pharm Co. Ltd. | 54 | 1 |
| BioCrea GmbH | 55 | 1 |
| BioHealthonomics Inc | 56 | 1 |
| Boehringer Ingelheim GmbH | 57 | 1 |
| Braeburn Pharmaceuticals, Inc. | 58 | 1 |
| Bristol-Myers Squibb Company | 59 | 1 |
| Critical Pharmaceuticals Limited | 60 | 1 |
| Curemark, LLC | 61 | 1 |
| Delpor, Inc. | 62 | 1 |
| Denovo Biopharma, LLC | 63 | 1 |
| Echo Pharmaceuticals B.V. | 64 | 1 |
| Egis Gyogyszergyar Nyrt | 65 | 1 |
| Evotec AG | 66 | 1 |
| F. Hoffmann-La Roche Ltd. | 67 | 1 |
| Fabre-Kramer Pharmaceuticals, Inc. | 68 | 1 |
| Galenea Corp. | 69 | 1 |
| GeNeuro SA | 70 | 1 |
| Glenmark Pharmaceuticals Ltd | 71 | 1 |
| GP Pharm, S.A. | 72 | 1 |
| GW Pharmaceuticals Plc | 73 | 1 |
| H. Lundbeck A/S | 74 | 1 |
| Heptares Therapeutics Limited | 75 | 1 |
| Hisamitsu Pharmaceutical Co., Inc. | 76 | 1 |
| Indivior Plc | 77 | 1 |
| INSYS Therapeutics, Inc. | 78 | 1 |
| Integrative Research Laboratories Sweden AB | 79 | 1 |
| IntelGenx Corp. | 80 | 1 |
| Intra-Cellular Therapies, Inc. | 81 | 1 |
| Jiangsu Nhwa Pharmaceutical Corporation Ltd. | 82 | 1 |
| Johnson &Johnson | 83 | 1 |
| Karuna Pharmaceuticals Inc. | 84 | 1 |
| KemPharm, Inc. | 85 | 1 |
| Laboratorios Farmaceuticos Rovi, S.A. | 86 | 1 |
| Lead Discovery Center GmbH | 87 | 1 |
| Lohocla Research Corporation | 88 | 1 |
| Luye Pharma Group Ltd. | 89 | 1 |
| Mapi Pharma Ltd. | 90 | 1 |
| Merck &Co., Inc. | 91 | 1 |
| Mitsubishi Tanabe Pharma Corporation | 92 | 1 |
| Neurocrine Biosciences, Inc. | 93 | 1 |
| NeurOp, Inc | 94 | 1 |
| Newron Pharmaceuticals S.p.A. | 95 | 1 |
| Omeros Corporation | 96 | 1 |
| Otsuka Holdings Co., Ltd. | 97 | 1 |
| Peptron, Inc. | 98 | 1 |
| Pfizer Inc. | 99 | 1 |
| Promentis Pharmaceuticals, Inc. | 100 | 1 |
| Ra Pharmaceuticals, Inc. | 101 | 1 |
| Reviva Pharmaceuticals Inc. | 102 | 1 |
| Richter Gedeon Nyrt. | 103 | 1 |
| SK Biopharmaceuticals Co., Ltd. | 104 | 1 |
| Sumitomo Dainippon Pharma Co., Ltd. | 105 | 1 |
| Sunovion Pharmaceuticals Inc. | 106 | 1 |
| Suven Life Sciences Ltd. | 107 | 1 |
| Taisho Pharmaceutical Holdings Co., Ltd. | 108 | 1 |
| Takeda Pharmaceutical Company Limited | 109 | 1 |
| Tetra Discovery Partners LLC | 110 | 1 |
| Teva Pharmaceutical Industries Ltd. | 111 | 1 |
| Vanda Pharmaceuticals Inc. | 112 | 1 |
| Vitality Biopharma Inc | 113 | 1 |
| VLP Therapeutics, LLC | 114 | 1 |
| Zogenix, Inc. | 115 | 1 |
| Zysis Limited | 116 | 1 |
| Schizophrenia Therapeutics Assessment | 117 | 17 |
| Assessment by Monotherapy Products | 117 | 1 |
| Assessment by Combination Products | 118 | 1 |
| Assessment by Target | 119 | 5 |
| Assessment by Mechanism of Action | 124 | 6 |
| Assessment by Route of Administration | 130 | 2 |
| Assessment by Molecule Type | 132 | 2 |
| Drug Profiles | 134 | 183 |
| (olanzapine + samidorphan l-malate) Drug Profile | 134 | 3 |
| (trospium chloride + xanomeline tartrate) Drug Profile | 137 | 1 |
| ADE-615 Drug Profile | 138 | 1 |
| ADE-616 Drug Profile | 139 | 1 |
| ADN-2013 Drug Profile | 140 | 1 |
| AG-0098 Drug Profile | 141 | 1 |
| AR-116082 Drug Profile | 142 | 1 |
| aripiprazole Drug Profile | 143 | 2 |
| aripiprazole CR Drug Profile | 145 | 1 |
| asenapine maleate Drug Profile | 146 | 1 |
| ASP-4345 Drug Profile | 147 | 1 |
| ATI-9242 Drug Profile | 148 | 1 |
| ATX-11004 Drug Profile | 149 | 1 |
| AUT-00206 Drug Profile | 150 | 1 |
| AVN-211 Drug Profile | 151 | 1 |
| AVP-786 Drug Profile | 152 | 3 |
| BI-409306 Drug Profile | 155 | 2 |
| blonanserin Drug Profile | 157 | 1 |
| BMS-952048 Drug Profile | 158 | 1 |
| BMS-955829 Drug Profile | 159 | 1 |
| BNC-375 Drug Profile | 160 | 1 |
| brexpiprazole Drug Profile | 161 | 6 |
| cannabidiol Drug Profile | 167 | 3 |
| cariprazine Drug Profile | 170 | 5 |
| CB-1407 Drug Profile | 175 | 1 |
| CB-2803 Drug Profile | 176 | 1 |
| clozapine Drug Profile | 177 | 1 |
| CM-182 Drug Profile | 178 | 1 |
| Drug to Agonize Muscarinic M4 Receptors for Psychiatric Diseases and Alzheimer's Disease Drug Profile | 179 | 1 |
| Drugs to Inhibit NOS1AP for Schizophrenia Drug Profile | 180 | 1 |
| ECP-012A Drug Profile | 181 | 1 |
| Egis-11150 Drug Profile | 182 | 1 |
| EPO-Variant Drug Profile | 183 | 1 |
| erythropoietin Drug Profile | 184 | 1 |
| evenamide Drug Profile | 185 | 3 |
| F-17464 Drug Profile | 188 | 1 |
| FKF-02SC Drug Profile | 189 | 1 |
| GNbAC-2 Drug Profile | 190 | 1 |
| GWP-42003 Drug Profile | 191 | 2 |
| histamine dihydrochloride Drug Profile | 193 | 1 |
| HPI-201 Drug Profile | 194 | 1 |
| HTL-18318 Drug Profile | 195 | 1 |
| HTL-9936 Drug Profile | 196 | 2 |
| iloperidone Drug Profile | 198 | 2 |
| INT-0036 Drug Profile | 200 | 1 |
| IRL-626 Drug Profile | 201 | 1 |
| ITI-007 Drug Profile | 202 | 9 |
| JNJ-40411813 Drug Profile | 211 | 3 |
| JNJ-46778212 Drug Profile | 214 | 1 |
| KP-303 Drug Profile | 215 | 1 |
| LuAF-11167 Drug Profile | 216 | 1 |
| LuAF-35700 Drug Profile | 217 | 1 |
| lurasidone hydrochloride Drug Profile | 218 | 9 |
| MGS-0028 Drug Profile | 227 | 1 |
| MK-8189 Drug Profile | 228 | 1 |
| Monoclonal Antibodies to Inhibit HERV-W for Schizophrenia Drug Profile | 229 | 1 |
| MT-210 Drug Profile | 230 | 3 |
| paliperidone palmitate Drug Profile | 233 | 1 |
| PBF-999 Drug Profile | 234 | 1 |
| PF-06266047 Drug Profile | 235 | 1 |
| PF-06412562 Drug Profile | 236 | 1 |
| PGW-5 Drug Profile | 237 | 1 |
| pomaglumetad methionil Drug Profile | 238 | 2 |
| PyP-1 Drug Profile | 240 | 1 |
| RG-7203 Drug Profile | 241 | 1 |
| risperidone Drug Profile | 242 | 1 |
| risperidone Drug Profile | 243 | 2 |
| risperidone Drug Profile | 245 | 1 |
| risperidone Drug Profile | 246 | 1 |
| risperidone Drug Profile | 247 | 1 |
| risperidone depot Drug Profile | 248 | 1 |
| risperidone ER Drug Profile | 249 | 1 |
| risperidone LAI Drug Profile | 250 | 1 |
| risperidone SR Drug Profile | 251 | 1 |
| risperidone SR Drug Profile | 252 | 1 |
| risperidone SR Drug Profile | 253 | 2 |
| risperidone SR Drug Profile | 255 | 1 |
| RO-5256390 Drug Profile | 256 | 1 |
| RO-5461861 Drug Profile | 257 | 1 |
| RP-5063 Drug Profile | 258 | 2 |
| SEP-363856 Drug Profile | 260 | 1 |
| SKLA-4R Drug Profile | 261 | 1 |
| Small Molecule to Agonize GABRA5 Receptor for CNS Disorders Drug Profile | 262 | 1 |
| Small Molecule to Agonize GPR52 for Schizophrenia Drug Profile | 263 | 1 |
| Small Molecule to Agonize Muscarinic Acetylcholine Receptor 4 for Schizophrenia Drug Profile | 264 | 1 |
| Small Molecule to Agonize Muscarinic M1 and M4 Receptors for Psychosis and Neurologic Diseases Drug Profile | 265 | 1 |
| Small Molecule to Antagonize 5-HT2A Receptor for Schizophrenia Drug Profile | 266 | 1 |
| Small Molecule to Antagonize Dopamine D1, D2 and D3 Receptors for Cocaine Use Disorder and Schizophrenia Drug Profile | 267 | 1 |
| Small Molecule to Antagonize GPR173 for Obesity and Schizophrenia Drug Profile | 268 | 1 |
| Small Molecule to Antagonize GPR27 for Diabetes, Obesity and Schizophrenia Drug Profile | 269 | 1 |
| Small Molecule to Antagonize GPR78 for Bipolar Disorder and Schizophrenia Drug Profile | 270 | 1 |
| Small Molecule to Antagonize GPR85 for Obesity and Schizophrenia Drug Profile | 271 | 1 |
| Small Molecule to Inhibit GlyT1 for Schizophrenia and Parkinson s Disease Drug Profile | 272 | 1 |
| Small Molecule to Inhibit PDE10 for Schizophrenia and Huntington's Disease Drug Profile | 273 | 1 |
| Small Molecule to Inhibit PDE10A for Schizophrenia Drug Profile | 274 | 1 |
| Small Molecule to Inhibit PDE10A for Schizophrenia Drug Profile | 275 | 1 |
| Small Molecule to Inhibit Serotonin, Histamine and Dopamine Receptors for Schizophrenia Drug Profile | 276 | 1 |
| Small Molecule to Inhibit VMAT-2 for Bipolar Disorder, Movement Disorders and Schizophrenia Drug Profile | 277 | 1 |
| Small Molecule to Target GPR151 for CNS Diseases Drug Profile | 278 | 1 |
| Small Molecule to Target GPR153 for Schizophrenia Drug Profile | 279 | 1 |
| Small Molecule to Target Nrg1-ErbB4 Pathway for Schizophrenia and Cardiovascular Diseases Drug Profile | 280 | 1 |
| Small Molecules 1 for Schizophrenia Drug Profile | 281 | 1 |
| Small Molecules for Schizophrenia Drug Profile | 282 | 1 |
| Small Molecules to Agonize 5-HT2C for Obesity and Schizophrenia Drug Profile | 283 | 1 |
| Small Molecules to Agonize Alpha-7 Nicotinic Acetylcholine Receptor for Alzheimer s Disease and Schizophrenia Drug Profile | 284 | 1 |
| Small Molecules to Agonize CB1 and CB2 for Central Nervous System Disorders Drug Profile | 285 | 1 |
| Small Molecules to Agonize CHRNA7 for Central Nervous System Drug Profile | 286 | 1 |
| Small Molecules to Agonize M1 for Schizophrenia and Alzheimer's Disease Drug Profile | 287 | 1 |
| Small Molecules to Agonize mGlu1 for Schizophrenia Drug Profile | 288 | 1 |
| Small Molecules to Agonize mGluR5 for Schizophrenia Drug Profile | 289 | 1 |
| Small Molecules to Agonize NMDA Receptor for Schizophrenia Drug Profile | 290 | 1 |
| Small Molecules to Antagonize GRIN2C and GRIN2D for Central Nervous System Disorders Drug Profile | 291 | 1 |
| Small Molecules to Inhibit PDE10A for Schizophrenia and Psychosis Drug Profile | 292 | 1 |
| Small Molecules to Inhibit PDE10A for Schizophrenia and Psychosis Drug Profile | 293 | 1 |
| Small Molecules to Inhibit PDE4D for Schizophrenia Drug Profile | 294 | 1 |
| Small Molecules to Inhibit PDE9 for Alzhiemer's Disease, Schizophrenia and Cognition Disorders Drug Profile | 295 | 1 |
| Small Molecules to Target 5-HT2C and 5-HT6 Receptor for Schizophrenia Drug Profile | 296 | 2 |
| Small Molecules to Target 5HT2 for CNS and Metabolic Disorders Drug Profile | 298 | 1 |
| Small Molecules to Target Glutamate System for Schizophrenia Drug Profile | 299 | 1 |
| sodium benzoate Drug Profile | 300 | 1 |
| Stem Cell Therapy to Activate DAT for Addictive Disorders and Schizophrenia Drug Profile | 301 | 1 |
| SUVN-501 Drug Profile | 302 | 2 |
| SUVN-502 Drug Profile | 304 | 2 |
| SUVN-507 Drug Profile | 306 | 1 |
| SUVN-512 Drug Profile | 307 | 1 |
| SUVND-4010 Drug Profile | 308 | 2 |
| Synthetic Peptide for Schizophrenia Drug Profile | 310 | 1 |
| Synthetic Peptides to Inhibit Complement C1s for Autoimmunity, Neurodegenerative Diseases and Schizophrenia Drug Profile | 311 | 1 |
| TAK-063 Drug Profile | 312 | 1 |
| TS-134 Drug Profile | 313 | 1 |
| Vaccine for Alzheimer s Disease and Schizophrenia Drug Profile | 314 | 1 |
| Vaccine for CNS Disorders Drug Profile | 315 | 1 |
| ziprasidone mesylate Drug Profile | 316 | 1 |
| Schizophrenia Dormant Projects | 317 | 14 |
| Schizophrenia Discontinued Products | 331 | 4 |
| Schizophrenia Product Development Milestones | 335 | 13 |
| Featured News &Press Releases | 335 | 1 |
| Oct 31, 2016: Intra-Cellular Therapies Presents the ITI-007 Clinical Development Program in Schizophrenia at the CNS Summit 2016 Annual Conference | 335 | 1 |
| Oct 27, 2016: Sunovion Announces Positive Clinical Study Results for Latuda (lurasidone HCl) in Adolescents with Schizophrenia | 335 | 1 |
| Oct 26, 2016: Minerva Neurosciences Announces Positive Data From Six-Month Extension of Phase IIb Trial of MIN-101 Monotherapy in Schizophrenia | 336 | 2 |
| Oct 17, 2016: Aequus Advances Clinical Development of Transdermal Aripiprazole Patch | 338 | 1 |
| Oct 13, 2016: Minerva Neurosciences Announces Acceptance of Presentation of Clinical Data With MIN-101 at American College of Neuropsychopharmacology Annual Meeting | 338 | 2 |
| Oct 03, 2016: Alkermes Announces Initiation of Clinical Study Evaluating Metabolic Profile of ALKS 3831 for Treatment of Schizophrenia | 340 | 1 |
| Sep 28, 2016: Intra-Cellular Therapies Announces Top-Line Results from the Second Phase 3 Trial of ITI-007 in Patients with Schizophrenia (Study 302) | 340 | 2 |
| Sep 26, 2016: Minerva Neurosciences Provides Update on MIN-101 Clinical Program | 342 | 1 |
| Sep 23, 2016: U.S. FDA Approves Labeling Update of REXULTI (brexpiprazole) for maintenance treatment of Schizophrenia | 342 | 1 |
| Sep 16, 2016: Sunovion to Present Data on Latuda (lurasidone) at the 29th European College of Neuropsychopharmacology (ECNP) Congress | 343 | 1 |
| Sep 12, 2016: Karuna Doses First Subject in Tolerability Proof-of-Concept Study of Lead Product Candidate | 344 | 1 |
| Aug 30, 2016: USPTO Dismisses Petition for Inter Partes Review of Fanapt Patent | 345 | 1 |
| Aug 26, 2016: Vanda Patents Found Valid and Infringed in Fanapt ANDA Litigation | 345 | 1 |